4Ibraghimov-Beskrovnaya O, Bukanov N. Polycystic kidney diseases: from molecular discoveries to targeted therapeutic strategies. Cell Mol Life Sci, 2008, 65: 605-619.
5Patel V, Chowdhury R, Igarashi P. Advances in the pathogenesis and treatment of polycystic kidney disease. Curr Opin Nephrol Hypertens, 2009, 18: 99-106.
7Yamaguchi T, Nagao S, Kasahara M, et al. Renal excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis, 1997, 20: 703- 709.
8Yang B, Sonawane ND, Zhao D, et al. Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol, 2008, 19: 1300-1310.
9Verkman AS. Renal concentrating and diluting function in deficiency of specific aquaporin genes. Exp Nephrol, 2002, 10: 235-240.
10Yang B, Zhao D, Verkman AS. Hsp90 inhibitor partially corrects nephrogenic diabetes insipidus in a conditional knock-in mouse model of aquaporin-2 mutation. FASEB J, 2009, 23: 503-512.
